Beta Bionics initiated with a Neutral at Goldman Sachs
Confident Investing Starts Here:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 hours ago
- Business Insider
Opera price target raised to $24.50 from $23.50 at Goldman Sachs
Goldman Sachs analyst Eric Sheridan raised the firm's price target on Opera (OPRA) to $24.50 from $23.50 and keeps a Buy rating on the shares. The company's Q2 results saw solid revenue momentum with strong trends in both search and advertising trends, the analyst tells investors in a research note. The launch of Mini Pay, a stablecoin product with 9M activated wallets and over 250M transactions is already demonstrating one of the fastest growing non-custodial wallets globally, the firm added. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yahoo
4 hours ago
- Yahoo
The Hanover Insurance Group, Inc. Announces Pricing of $500 Million Senior Notes Offering
WORCESTER, Mass., Aug. 19, 2025 /PRNewswire/ -- The Hanover Insurance Group, Inc. (NYSE: THG) today announced it has priced a registered offering of $500 million aggregate principal amount of senior, unsecured 5.50% notes due September 1, 2035 (the "Notes"). The company plans to use the net proceeds from the issuance of the Notes to repay its outstanding 7.625% Senior Notes due October 2025, repay or redeem its outstanding 4.500% Senior Notes due April 2026 (collectively, the "Debentures") and for general corporate purposes. The company anticipates the debt offering will close on or around August 21, 2025, subject to customary closing conditions. Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and Morgan Stanley & Co. LLC are acting as the joint book-running managers for the offering. Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any sale of the Notes in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification under the securities laws of any such state or jurisdiction. The offering is being made pursuant to an effective shelf registration filed with the Securities and Exchange Commission ("SEC") on August 18, 2025. A prospectus and prospectus supplement related to this offering have been filed with the SEC. This press release does not constitute a notice of redemption with respect to, or any offer to purchase, the Debentures. Any such notice will be given to holders of the Debentures in a manner prescribed in the indenture governing the Debentures. Copies of the prospectus and related prospectus supplement may be obtained at no cost by visiting the SEC website at Alternatively, copies or information concerning this offering may be obtained by contacting the joint book-running managers: Goldman Sachs & Co. LLC at +1 (800) 828-3182, J.P. Morgan Securities LLC at +1 (212) 834-4533, or Morgan Stanley & Co. LLC at +1 (866) 718-1649. About The Hanover The Hanover Insurance Group, Inc. is the holding company for several property and casualty insurance companies, which together constitute one of the largest insurance businesses in the United States. The company provides exceptional insurance solutions through a select group of independent agents and brokers. Together with its agent partners, The Hanover offers standard and specialized insurance protection for small and mid-sized businesses, as well as for homes, automobiles, and other personal items. Forward-Looking Statements This news release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Those forward-looking statements are subject to various risks and uncertainties and include all statements that are not historical statements of fact and those regarding our intent, belief or expectations with respect to future events and financial performance and the debt offering, including the expected closing of the debt offering and the use of proceeds from the debt offering. The company cautions investors that any such forward-looking statements are not guarantees of future performance, and actual results could differ materially. Investors are directed to consider the risks and uncertainties in the company's business that may affect future performance and that are discussed in readily available documents, including those risks which are discussed in the company's annual report and other documents filed by the company with the SEC. Contacts: Investors: Media:Oksana Lukasheva Emily P. Trevallion(508) 525-6081 (508) 855-3263Email: olukasheva@ Email: etrevallion@ View original content to download multimedia: SOURCE The Hanover Insurance Group, Inc.
Yahoo
6 hours ago
- Yahoo
Type 2 diabetes patients set for major shake-up in care
People with type 2 diabetes in England are to get the biggest shake up of care in a decade which could see them offered treatments, including jabs that aid weight-loss, sooner. The health service should move from a one-size-fits-all approach of starting everyone on the same medication, to more personalised care that aims to prevent complications like heart failure and heart attacks, according to new draft guidance from the National Institute for Health and Care Excellence (Nice). This includes making newer type 2 diabetes drugs, known as SGLT-2 inhibitors, a first-line treatment option in a move that could eventually help save tens of thousands of lives. SGLT-2 inhibitors, which include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, are once-a-day tablets that reduce blood sugar levels by helping the kidneys remove glucose, which is passed from the body through urine. However, analysis by Nice found these drugs are under-prescribed. The new guidelines recommend patients who cannot tolerate metformin – the first-choice in type 2 diabetes medication – should start with an SGLT-2 inhibitor on its own. The decision comes after evidence suggested these drugs protect the heart and kidneys as well as controlling blood sugar, Nice said. It is estimated the change could save almost 22,000 lives once uptake reaches 90% of the population. Nice also suggests some groups of patients would also benefit from GLP-1 receptor agonists such as liraglutide or semaglutide sooner, rather than keeping them for the later stages of treatment. Semaglutide, sold under the brand name Ozempic, is licensed in the UK to treat type 2 diabetes, while its other brand – Wegovy – is also used by the NHS to help obese people lose weight. Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice, said: 'This guidance means more people will be offered medicines where it is right to do so to reduce their future risk of ill health. 'This represents a significant evolution in how we approach type 2 diabetes treatment. 'We're moving beyond simply managing blood sugar to taking a holistic view of a person's health, particularly their cardiovascular and kidney health. 'The evidence shows that certain medicines can provide important cardiovascular benefits, and by recommending them as part of initial treatment, we could help prevent heart attacks, strokes and other serious complications before they occur. 'This is particularly important given that cardiovascular disease is the leading cause of death in people with type 2 diabetes.' Around 4.6 million people in the UK are living with diabetes, with nine in 10 of those having type 2. However, it is estimated that a further 1.3 million people may have undiagnosed type 2 diabetes. Nice analysed the records of 590,000 people and found SGLT-2 inhibitors are under-prescribed, particularly to women, older people, and black patients. Prof Benger added: 'The evidence from our analysis is clear. There are prescribing gaps that need to be addressed. 'The guideline update published today will help to increase equitable uptake of SGLT-2 inhibitors, which we know can prevent serious health complications.' Dr Waqaar Shah, chairman of the guideline committee, added: 'We know that SGLT-2 inhibitors are currently under-prescribed, and our health economics analysis shows that people living in the most deprived areas would particularly benefit from universal access to these treatments. 'These recommendations could help reduce health inequalities while providing better outcomes for everyone.' Elsewhere, the draft guidance suggests different treatments for diabetes patients with certain characteristics or health conditions. These include adults with cardiovascular disease, who should be offered a triple therapy including a GLP-1 receptor agonist. Meanwhile, adults diagnosed with type 2 diabetes before 40 should be offered dual therapy before a GLP-1 receptor agonist is considered, while patients with chronic kidney disease should have tailored recommendations based on their kidney function. A public consultation on the new Nice guidelines is open until October 2. Douglas Twenefour, head of clinical at Diabetes UK, said: 'This long-awaited announcement propels type 2 diabetes treatment into the 21st century. 'Boosting access to newer treatments will be transformative for people with type 2 diabetes, while ensuring the UK keeps pace with the global momentum in treating the condition. 'The majority of people with type 2 diabetes are not currently taking the most effective medication for them, putting them at risk of devastating diabetes-related complications. 'Diabetes is a leading cause of cardiovascular disease, and tailoring treatment based on individual risk could protect thousands against heart attacks and kidney disease. 'These guidelines could go a long way to easing the burden of living with this relentless condition, as well as helping to address inequities in type 2 diabetes treatments and outcomes.'
